{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"75.2","upperLimit":"97.1","value":"89.5"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"38"}],"units":"Participants"}],"description":"Calculated by the number of tumor responses divided by the total number of evaluable patients. An exact binomial confidence interval will be calculated.","dispersionType":"95% Confidence Interval","groups":[{"description":"Patients receive:\n\nCycle 1:\n\n250 mg/m\\^2 rituximab IV on days 1 and 8, 2 mg (5.0mCi of In-111) Indium (In-111 ibritumomab tiuxetan) IV over 10 minutes on day 1, 0.4 mCi/kg Yttrium (Y-90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8\n\nCycle 2 (Cycle 2 delivered 24-36 weeks after Cycle 1):\n\n250 mg/m\\^2 rituximab IV on days 1 and 8, 2 mg (5.0mCi of In-111) Indium (In-111 ibritumomab tiuxetan) IV over 10 minutes on day 1, 0.4 mCi/kg Yttrium (Y-90 ibritumomab tiuxetan (IDEC-90Y2B8) IV over 10 minutes on day 8.\n\nPatients also receive:\n\n480 mcg filgrastim (G-CSF) subcutaneously (SC) daily when ANC is less than 1500.\n\n50 micrograms/kg Interleukin-11 SC when PLT counts less than 150,000.","id":"OG000","title":"Treatment : Dose Level 6"}],"paramType":"NUMBER","populationDescription":"All eligible phase II patients. One of the 39 phase II patients was deemed ineligible","reportingStatus":"POSTED","timeFrame":"Assessed up to 5 years","title":"Tumor Response Rate (Phase II)","type":"SECONDARY","unitOfMeasure":"percentage of patients with response"}